clinical trial · NCT06760156
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
H. Lee Moffitt Cancer Center and Research Institute·phase2·recruiting·n = 28
Large B-cell LymphomaTafasitamabLenalidomide
brief summary
The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.
started
Mar 19, 2025
primary completion
Jan 1, 2027
completion
Jan 1, 2028
last updated
Apr 3, 2026
official title
Phase 2 Study of Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lymphoma After Axicabtagene Ciloleucel
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol